AHA Coding Clinic® for ICD-10-CM and ICD-10-PCS - 2021 Issue 4; Section X-New Technology
Introduction of New Therapeutic Substances
Effective October 1, 2021, eight new substance values were added to code Table XW0, Anatomical Regions, Introduction, for the eight substances listed below. Please note that all of the substances below have a qualifier of 7, New Technology Group 7. Device/Substance/Technology 2 Bromelain-enriched Proteolytic Enzyme 5 Narsoplimab Monoclonal Antibody 6 Terlipressin 7 Trilaciclib 8 Lurbinectedin 9 Satralizumab-mwge B Amivantamab Monoclonal Antibody L Lifileucel Immunotherapy Bromelain-enriched Proteolytic Enzyme NexoBrid™ is a mixture of proteolytic enzymes (enriched in bromelain) used for eschar removal in adults with deep partial thickness and/or full thickness thermal burns. The proteolytic enzymes can be applied...
Subscribe or sign in to view the full article.
Article Overview
This Coding Clinic article summarizes newly added therapeutic substance values in ICD-10-PCS effective October 1, 2021 and explains the clinical context for several new drugs and cell-based immunotherapy products. It is relevant to inpatient coders, clinical documentation specialists, CDI teams, and revenue integrity staff who need to understand which therapies prompted new PCS code creation and related diagnosis coding updates. The article covers multiple specialty areas, including oncology, burns, hematology, liver disease, autoimmune neurology, and transplant-related complications.
Why This Topic Matters
New therapeutic substances can require new procedure codes and, in some cases, related diagnosis codes. Understanding the scope of these additions helps coding professionals stay aligned with current ICD-10-PCS and ICD-10-CM updates.
Article Sections
-
Effective October 1, 2021: New substance values in Table XW0
Introduces the group of newly added therapeutic substance values and notes the shared qualifier referenced for these updates.
-
Bromelain-enriched Proteolytic Enzyme
Discusses the clinical context for a burn-related enzymatic product and the related procedural coding update.
-
Narsoplimab
Describes the therapy’s use in a transplant-related complication and notes associated procedure and diagnosis coding changes.
-
Terlipressin
Reviews the therapy’s clinical indication and the corresponding coding update for intravenous administration.
-
Trilaciclib
Summarizes an oncology supportive-care therapy and its use in reducing treatment-related myelosuppression.
-
Lurbinectedin
Presents the therapeutic context for a cancer treatment agent and its administration details.
-
Satralizumab-mwge
Covers a biologic therapy used for an autoimmune neurologic disorder and its route of administration.
-
Amivantamab
Describes an oncology monoclonal antibody therapy and its treatment setting.
-
Lifileucel Immunotherapy
Explains a cell-based immunotherapy product and its role in treating solid tumors, including melanoma.
What You Will Learn
- Which newly added therapeutic substances are discussed in the ICD-10-PCS update
- What clinical categories of therapies triggered new procedure code creation
- Which therapies are associated with related diagnosis coding changes
- How the article groups the updates by drug or therapy type
- Which medical specialties and conditions are represented in the update
Who Should Read This
- Inpatient medical coders
- Clinical documentation integrity specialists
- Revenue cycle professionals
- Coding educators
- Health information management staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com